Oxygesic Akut

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxygesic Akut (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxygesic Akut, is an opioid analgesic presented as an oral tablet for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient.

GNH India supplies Oxygesic Akut as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mundipharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone Hydrochloride is an opioid that acts on the central nervous system to relieve pain.

Acute postoperative pain: provides rapid analgesia after surgical procedures.
Cancer‑related pain: helps control moderate to severe malignant pain.
Severe chronic non‑cancer pain: reduces persistent pain when alternative therapies have failed.

How It Works

Oxycodone binds preferentially to mu‑opioid receptors in the brain and spinal cord, inhibiting the release of excitatory neurotransmitters such as substance P and glutamate. This receptor activation reduces neuronal excitability and alters pain perception, producing analgesia while also affecting respiratory and gastrointestinal centers.

Side Effects

Common Side Effects

Nausea: feeling of sickness or urge to vomit.
Constipation: reduced bowel movements and hard stools.
Drowsiness: increased sleepiness or fatigue.
Dizziness: sensation of light‑headedness or unsteadiness.
Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure causing faintness.
Opioid dependence or addiction: compulsive use despite harmful consequences.
Allergic reactions: rash, itching, swelling, or anaphylaxis.
Seizures: rare occurrence of convulsive episodes.

Precautions & Warnings

Before prescribing Oxygesic Akut, clinicians should evaluate patient risk factors and monitor for adverse events.

Assess pain severity and opioid suitability: ensure opioid therapy is appropriate for the clinical situation.
Monitor respiratory function: watch for signs of respiratory depression, especially after dose changes.
Avoid use in severe respiratory disease: contraindicated in patients with uncontrolled asthma or COPD.
Counsel on constipation risk: advise prophylactic laxatives and adequate hydration.
Store at ambient temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Oxygesic Akut can interact with several drug classes, altering its safety or efficacy.

Major Interactions (Avoid)

Other opioids: additive risk of respiratory depression and profound sedation.
Benzodiazepines: synergistic central nervous system depression leading to profound sedation.
Monoamine oxidase inhibitors (MAOIs): may cause severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): increase oxycodone plasma concentrations.
CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce oxycodone effectiveness.
Alcohol: enhances sedative effects and may worsen respiratory depression.

Frequently Asked Questions

Oxygesic Akut contains oxycodone hydrochloride, an opioid analgesic prescribed to manage moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic non‑cancer pain when other treatments are inadequate.

Oxycodone binds to mu‑opioid receptors in the central nervous system, inhibiting the release of pain‑transmitting neurotransmitters. This reduces neuronal excitability and alters the perception of pain, providing effective analgesia.

The specific dose of Oxygesic Akut is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and individual health factors. Dosage adjustments are made according to clinical response and safety considerations.

Oxycodone crosses the placenta and is excreted in breast milk. Use during pregnancy or lactation is only considered when the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Oxygesic Akut delivers oxycodone, which offers potent mu‑opioid receptor activation and a relatively rapid onset of action compared with some longer‑acting opioids like morphine. Its pharmacokinetic profile may provide more predictable pain control, but individual response varies.

Store Oxygesic Akut at ambient temperature, below 25 °C, in the original packaging. Protect it from moisture, direct sunlight, and excessive heat to maintain potency and stability.

Oxygesic Akut is taken orally, usually as a whole tablet swallowed with water. The exact route, frequency, and timing are directed by the prescribing healthcare professional.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or addiction, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely, especially during dose initiation or escalation.

Oxygesic Akut is contraindicated in patients with known hypersensitivity to oxycodone or any component of the formulation, those with severe respiratory insufficiency, acute or severe asthma, and individuals taking MAO inhibitors within 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.